Auxilium Pharmaceuticals, Inc. has amended its manufacturing agreement with UK-based Cobra Biologics, Ltd. Under the amended agreement, Cobra will complete one BLA batch of the active ingredient for AA4500, the company’s injectable enzyme. The revised agreement is a result of Auxilium’s decision to move forward with its facility in Horsham, PA to support the BLA submission and to serve as a primary source of the commercial supply of AA4500. Auxilium will use the materials in on...